Cargando…
Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers
BACKGROUND: Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells combined with checkpoint inhibition may prevent T cell exhaustion and improve clinical outcomes. However, the approach is limited by cumulative costs and toxicities. METHODS: To overcome this drawback, we created a C...
Autores principales: | Yang, Zhifen, Li, Lingyu, Turkoz, Ahu, Chen, Pohan, Harari-Steinfeld, Rona, Bobbin, Maggie, Stefanson, Ofir, Choi, Hana, Pietrobon, Violena, Alphson, Bennett, Goswami, Angshumala, Balan, Vitaly, Kearney, Alper, Patel, Dharmesh, Yang, Jin, Inel, Damla, Vinod, Veena, Cesano, Alessandra, Wang, Bing, Roh, Kyung-Ho, Qi, Lei S., Marincola, Francesco M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573881/ https://www.ncbi.nlm.nih.gov/pubmed/34743703 http://dx.doi.org/10.1186/s12967-021-03132-6 |
Ejemplares similares
-
Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment
por: Yang, Zhifen, et al.
Publicado: (2023) -
Improving CAR T-Cell Persistence
por: Pietrobon, Violena, et al.
Publicado: (2021) -
Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKɛ complex inhibitor BX795
por: Li, Lingyu, et al.
Publicado: (2020) -
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
por: Pietrobon, Violena, et al.
Publicado: (2021) -
Hypoxia and the phenomenon of immune exclusion
por: Pietrobon, Violena, et al.
Publicado: (2021)